Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Ipca Laboratories Ltd Performance

Today's Low
1,324.10
arrowIcon
Today's High
1,347.50
52 Wk Low
669.80
arrowIcon
52 Wk High
1,374.60


Open

1330.6

Traded Value (Cr)

32.62 Cr

Prev. Close

1352.3

VWAP

1338.77

Volume

9,85,533

Face Value

1

Ipca Laboratories Ltd Fundamentals

Market Cap
₹ 33,566 Cr
P/E Ratio (TTM)
65.56
P/B Ratio
5.46
Debt to Equity
0.32
ROE
8.01 %
EPS (TTM)
20.18
Dividend Yield
0.30%
Book Value
242.36

Click here to know more about Fundamentals

Ipca Laboratories Ltd F&O

Ipca Laboratories Ltd Option Chain

Ipca Laboratories Ltd Financials

Ipca Laboratories Ltd Financials

Ipca Laboratories Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 46.30 % 46.29 % 46.29 % 46.29 %
Mutual Funds 28.83 % 29.25 % 30.23 % 30.27 %
FII 10.51 % 10.27 % 9.86 % 10.05 %
Others 7.23 % 7.07 % 6.49 % 6.41 %
Retail 7.13 % 7.12 % 7.14 % 6.98 %

Promoters

46.30%

Mutual Funds

28.83%

FII

10.51%

Others

7.23%

Retail

7.13%

Promoters

46.29%

Mutual Funds

29.25%

FII

10.27%

Others

7.07%

Retail

7.12%

Promoters

46.29%

Mutual Funds

30.23%

FII

9.86%

Others

6.49%

Retail

7.14%

Promoters

46.29%

Mutual Funds

30.27%

FII

10.05%

Others

6.41%

Retail

6.98%

Resistance and Support

₹1,339.43

PIVOT

resistance-arrow
Resistance
First Resistance₹1,362.817
Second Resistance₹1,384.133
Third Resistance₹1,407.517
support-arrow
Support
First Resistance₹1,318.117
Second Resistance₹1,294.733
Third Resistance₹1,273.417
RSI75.752
MACD83.041
ADX37.366
CCI84.378

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day985,53392,00537.74
Week692,975361,94460.85
1 Month826,186378,72545.87
6 Months985,533564,14657.24

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19th October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments. The products of the Company are now sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries. Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over. The name of the company was changed to Ipca Laboratories Limited' in 6th August of the year 1964 and again name was changed to Ipca Laboratories Private Limited' in 13th January of the year 1966. Ipca had commissioned one of the first modern Pharma factory of yesteryears in the year 1969 at Mumbai. The present management took over the company in November of the year 1975. In the year 1976, started domestic marketing operations, the first company to offer sugarcoated Chloroquine tablets. Launched formulations of Metoclopramide under brand name 'Perinorm' for the first time in India during the year 1978. After two years, in 1980, the company had launched formulations of Bromhexine for the first time in India. Ipca's first APIs plant was commissioned at Ratlam in the year 1984 and also in the same period the second formulations plant was commissioned at Ratlam itself. Ipca's first APIs Plant for manufacturing of Chloroquine Phosphate was set up at Ratlam in the year 1986. As at 9th August 1988, again the company had changed its name to Ipca Laboratories Limited'. Ipca's status was converted to a Public Limited Company in 24th March of the year 1993 and also in the same year, the company had acquired Hoechst India's formulations unit at Kandla. During the year 1994, Ipca had acquired API Plant from BDH Pharmaceuticals (a subsidiary of E. Merck) at Indore. In the year 1995, the modern formulations plant at Athal (Silvassa) came to line. After a year, in 1996, the company had commissioned new API R&D Centre at Mumbai. In 2000, received ISO 9001 certification for Athal Plant. The Company had incorporated two subsidiaries in Mauritius in the year of 2001 under the name of Solway Investments Ltd and 'Sundridge Management Ltd. during the year 2002, launched new domestic marketing division, Intima to promote established brands with a focus on micro-interior marketing and also in the same year incorporated wholly owned subsidiary in Brazil under the name of Laboratories Ipca Do Brasil Ltd. Launched new domestic marketing division in the year 2003 as Activa, dedicated to Rheumatology Care. Forbes, a leading US business magazine, selected among its top 200 successful, rising companies outside USA in the same year 2003. Commissioned new formulation plant at Silvassa in the year 2004. Forbes selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia. Innotech Pharma Limited was merged with Ipca in August of the year 2005. During the same year, Ipca entered in to Joint Venture with Holley Group of China for marketing Artemisinin based API and Formulation. Joint Venture setup in SAIF Zone, Sharjah, U.A.E. and named as ACTIVA Pharmaceuticals FZC. Also acquired Cardiac brand ISORDIL from Wyeth Limited. Ipca had entered into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the U.S market in the year 2006. The Company's new plant at Dehradun was commenced operation from 5th May of the year 2006. As of January 2007, Ipca and Ranbaxy alliance had received U.S. FDA marketing approval for Atenolol Tablets. Ipca's New Biotech Research & Development Unit was inaugurated at Mumbai in March of the same year 2007. Ipca had awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. Ipca had received final approval from the US FDA, for Metoclopramide tablets in June 2008. The Company had signed a partnership agreement with Clinton Foundation in July of the same year 2008. The Company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower, latest instrumentation to upgrade and strengthen R&D facilities. Also, the company aims at developing newer drug delivery systems along with developing formulations for developed market and bio-equivalence studies of the same. During the FY 2015, the Company acquired assets of formulations manufacturing unit situated at Plot No. T-139, MIDC,Tarapur, Palghar - 401506. The Company has also acquired as a going concern on slump sale basis the High Potency (Hormonal) Oral Solid Dosage formulations manufacturing unit situated at Sector III, Pithampur, Dhar (Madhya Pradesh) together with its employees. This manufacturing unit has the approval of WHO-GMP, INVIMA Colombia and German. During the year 2015, the Company acquired joint management stake in M/s. Krebs Biochemicals & Industries Ltd., a listed public limited company with fermentation based APIs manufacturing facilities situated at Visakhapatnam and Nellore (Andhra Pradesh). The Company had also made public announcement of open offer to the public shareholders of the said company under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. M/s. Krebs Biochemicals and Industries Ltd. became an associate company. No other company has become / ceased to be subsidiary or joint venture or associate company during the financial year 2015. During the year, as a part of group re-construction, Ipca Laboratories (UK) Ltd. acquired the entire issued share capital of Onyx Scientific Ltd., UK from its wholly owned subsidiary, Onyx Research Chemicals Ltd., U.K. on 25th March, 2015 in lieu of capital dividend declared by the said company. Consequent to this, Onyx Scientific Ltd., UK has become wholly owned subsidiary of Ipca Laboratories (UK) Ltd. from the said date. From the said date, Onyx Research Chemicals Ltd. UK has ceased to trade and is in the process of being dissolved. The wholly owned subsidiary company, Ipca Pharmaceuticals (Shanghai) Ltd., incorporated in the Peoples Republic of China, is in the process of being voluntarily closed down. During the year 2016, the wholly owned subsidiary companies, Ipca Pharmaceuticals (Shanghai) Ltd. incorporated in the People's Republic of China and National Druggists Pty Ltd. incorporated in the Republic of South Africa were voluntarily closed down. Onyx Research Chemicals Limited, U.K. merged with its holding company Ipca Laboratories (UK) Ltd. Consequent to this, Onyx Scientific Ltd. has now become wholly owned subsidiary of Ipca Laboratories (U.K.) Ltd. which in turn is the wholly owned subsidiary of the Company. During the year 2018, the Company acquired 100% share capital of Pisgah Labs Inc. a North Carolina Corporation, Old Hendersonville Highway, Pisgah Forest, North Carolina, USA through Ipca Pharmaceutical Inc., USA (Company's wholly owned subsidiary) and Onyx Scientific Ltd., U.K (Onyx) (Company's wholly owned step down subsidiary) for US$ 9.65 millions, free of debt. Pisgah was founded as a contract manufacturer and developer of active pharmaceutical ingredients (APIs) and intermediates. During the year 2019-20, the Company acquired 100% paid-up share capital of M/s. Ramdev Chemical Private Limited on 24th April, 2019 and became its wholly owned subsidiary. During the year 2021, M/s. Trophic Wellness Private Ltd., got incorporated with the Company and became its subsidiary. During year 2022, Company acquired 26.57% of share capital of M/s. Lyka Labs Limited with the Promoters of the said Company. It made a Public Offer to acquire additional 26% Equity Shares of the said Company from its public shareholders, where the Company now holds 26.58% of the equity share capital of the said Company. During the financial year 2022-23, the Company acquired further 6.53% of the paid-up equity share capital of Trophic Wellness Private Ltd. With this acquisition, the Company holds 58.88% of the paid-up equity share capital of the said Company. During the financial year 2022-23, the Company acquired, thru preferential allotment, further 4.78% of the paid-up equity share capital of Lyka Labs Ltd. Also, in the month of April, 2023, the Company acquired another 4.98% of the paid-up share capital of the said company thru part conversion of warrants issued on preferential basis. With these share allotments, the Company now holds 36.34% of the paid-up equity share capital of Lyka Labs Ltd. During 2022-23, the merger of M/s. Ramdev Chemical Pvt. Ltd. and M/s. Tonira Exports Ltd., Company's wholly owned subsidiaries with the Company was effective from 1st April, 2022. The Company's Active Pharmaceuticals Ingredients (APIs) at Dewas (Madhya Pradesh) commenced trial production in September, 2022.

Managing Director

Pranay Godha

Founded

1949

NSE Symbol

IPCALAB

Ipca Laboratories Ltd Management

NameDesignation
Premchand GodhaChairman / Executive Director
A K JainJoint Managing Director & CFO
Pranay GodhaED / MD / CEO / Promoter
Prashant GodhaExecutive Director
Anand T KusreIndependent Non Exe. Director
Manisha PremnathIndependent Non Exe. Director
Kamal Kishore SethIndependent Non Exe. Director
Narendra MairpadyIndependent Non Exe. Director
Harish P KamathCompany Sec. & Compli. Officer

Ipca Laboratories Ltd News

Ipca Laboratories hikes stake in Lyka Labs
Through conversion of warrants
Ipca Labs inks pact with Omexa Formulary
Ipca Laboratories said that it has entered into a technology transfer agreement with Omexa Formulary private for a biosimilar clone, process development.
Ipca Laboratories Ltd soars 0.32%, up for fifth straight session
Ipca Laboratories Ltd is quoting at Rs 1204.7, up 0.32% on the day as on 12:44 IST on the NSE. The stock is up 52.2% in last one year as compared to a 30.72% spurt in NIFTY and a 58.98% spurt in the Nifty Pharma.
Ipca Laboratories Ltd rises for third straight session
Ipca Laboratories Ltd is quoting at Rs 1198.8, up 2.1% on the day as on 12:49 IST on the NSE. The stock is up 52.83% in last one year as compared to a 29.37% jump in NIFTY and a 59.35% jump in the Nifty Pharma index.
Ipca Laboratories appoints director
With effect from 14 February 2024
Ipca Laboratories Ltd eases for fifth straight session
Ipca Laboratories Ltd is quoting at Rs 1143.8, down 1.45% on the day as on 13:19 IST on the NSE. The stock jumped 35.59% in last one year as compared to a 20.34% rally in NIFTY and a 50.7% spurt in the Nifty Pharma index.
Ipca Laboratories Ltd rises for third consecutive session
Ipca Laboratories Ltd is quoting at Rs 1111, up 1.14% on the day as on 12:49 IST on the NSE. The stock is up 30.48% in last one year as compared to a 20.93% spurt in NIFTY and a 40.03% spurt in the Nifty Pharma index.
Ipca Laboratories to convene board meeting
On 14 February 2024
Ipca Laboratories Ltd soars 0.42%, up for fifth straight session
Ipca Laboratories Ltd is quoting at Rs 1124.1, up 0.42% on the day as on 12:44 IST on the NSE. The stock is up 32.25% in last one year as compared to a 18.69% spurt in NIFTY and a 36.18% spurt in the Nifty Pharma.
Ipca Laboratories Ltd soars 0.41%, gains for fifth straight session
Ipca Laboratories Ltd is quoting at Rs 1137.6, up 0.41% on the day as on 12:44 IST on the NSE. The stock is up 30.98% in last one year as compared to a 8.46% jump in NIFTY and a 24.45% jump in the Nifty Pharma.

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,65,370 Cr
₹ 1,522.80
(0.42 %)
88.68
CIPLA₹ 1,08,655 Cr
₹ 1,345.75
(-0.12 %)
33.03
DRREDDY₹ 99,137 Cr
₹ 5,942.85
(-0.24 %)
24.91
DIVISLAB₹ 97,472 Cr
₹ 3,671.70
(-1.00 %)
71.41
MANKIND₹ 93,635 Cr
₹ 2,337.45
(-2.43 %)
56.69

Ipca Laboratories Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Ipca Laboratories Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Ipca Laboratories Ltd's share price is ₹1,337.95 as of April 19, 2024

Ipca Laboratories Ltd's P/E ratio is 65.56 times as of April 19, 2024.

Ipca Laboratories Ltd's most recent financial reports indicate a price-to-book ratio of 5.46, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Ipca Laboratories Ltd's market is 33,566 Cr as on April 19, 2024.

The current financial records of Ipca Laboratories Ltd show a 8.01% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Ipca Laboratories Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Ipca Laboratories Ltd's 52-week high and low as of April 19, 2024 are ₹1347.5 and ₹1324.1 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Ipca Laboratories Ltd stands at 46.30%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 10.27% to 10.51%.